Skip to main content
HNGE logo

HNGE · Hinge Health, Inc.

Track HNGE — free
$120.95 +5.56 (+4.82%)
Market Cap
$9.38B
Shares
81.27M
Volume · Nov 16 569.13K Avg daily vol (3M) 1.89M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$115.39 Open$121.34 Day$112.80–121.45 52W close$31.17–123.23 Avg vol 30d2.0M Short int5.0M · 6.1% of shares · 2.4d Short vol32% Last earningsNov 2, 2026 DataMay 2025–Nov 2026 Filing10-Q · Nov 9

Up next

Feb 9, 2027 Est · unconfirmed · in 12 wks

Latest documents

2026
Nov 9
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue rises 51% as nine-month net income turns positive

Hinge Health reported nine-month revenue growth of 51%, primarily from existing clients, and net income of 136,217 (in thousands) versus a loss of 560,356 (in thousands).

Revenue $234.97M ▲ 52.4% Net income $57.4M Diluted EPS $0.66
Read from the MD&A section
4 source passages
Hinge Health leverages software, including AI, to automate care for joint and muscle health, migraine, and gastrointestinal (GI) conditions, delivering an outstanding member experience, improved member outcomes, and cost reductions for our clients. Revenue for the nine months ended September 30, 2026 increased by $213.0 million, or 51%, compared to the nine months ended September 30, 2025. The increases were primarily due to revenue growth from existing clients. | Net income (loss) | 57,398 | (1,844) | 136,217 | (560,356) | Open the document at this passage
Nov 2
Earnings call
Q3 2026 earnings call

Hinge Health reported Q3 revenue of $235 million, up 52%, and raised 2026 revenue guidance to $879 million to $881 million. Jim Pursley will step down as president at year-end and join the board.

Read from the first part of this long document
Nov 2
Current report 8-K Events of Oct 29
Revenue up 52%, full-year guidance raised

Hinge Health, Inc. reported third-quarter revenue of $235.0 million, up 52% year-over-year, and raised full-year 2026 revenue guidance to between $879 million and $881 million; non-GAAP operating margin guidance is 30% at the midpoint.

Financial results, Director or officer change, or executive pay, Regulation FD disclosure Read from the first part of this long document
3 source passages
Hinge Health, Inc. (NYSE: HNGE) today announced financial results for the third quarter ended September 30, 2026 and provided a business update. Revenue increased 52% year-over-year to $235.0 million compared to revenue of $154.2 million in Q3 2025. Full Year 2026: We are raising our revenue guidance to be between $879 million and $881 million, reflecting year-over-year growth of 50% at the midpoint. We are raising our non-GAAP income from operations guidance to be between $266 million and $268 million, reflecting year-over-year growth of 123% and non-GAAP operating margin of 30% at the midpoint, a ~1,000 bps increase over 2025. Open the document at this passage
Aug 6
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $212.82M ▲ 53.0% Net income $43.69M Diluted EPS $0.52
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$800.82M
Trailing 12 months
Net income (TTM)
$168.31M
Trailing 12 months
Revenue growth YoY
+52.4%
Year over year
Operating margin
18.7%
Trailing 12 months
P / E (TTM)
20.5
Trailing earnings · reciprocal yield 4.9%
FCF yield
3.4%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$211.55M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+9.7%
Year over year · more shares
Price change (1Y)
+176.4%
Trailing year
Short interest
6.1%
Latest settlement · 2.4 days to cover
View all 125 metrics

AI Brief

Q2 FY26 earnings call · Aug 4, 2026
Q2 FY26

TL;DR. Hinge Health posted Q2 revenue of $213 million (53% YoY growth) and raised full-year 2026 revenue guidance to $856–$860 million alongside higher operating income guidance, while announcing a $105 million cash acquisition of Cylinder Health to enter GI care and a $300 million increase to its share repurchase authorization.

Bullish
  • + Q2 revenue grew 53% YoY to $213 million, well above the $200–$202 million guidance range.
  • + LTM calculated billings grew 52% YoY to $862 million, supporting continued revenue momentum.
  • + Non-GAAP operating margin expanded to 29% from 19% a year ago and free cash flow tripled YoY to $100 million.
  • + Yield is now expected to reach ~4.45% for the year, driving durable billings and revenue outperformance.
  • + Migraine program launched within the quarter has gained 450+ clients covering more than 5 million lives.
  • + Hinge Health signed a definitive agreement to acquire Cylinder Health for $105 million in cash to enter GI care.
Bearish
  • − Cylinder Health acquisition will deploy $105 million in cash and bring near-term losses that must be integrated over the next year or two.
  • − GAAP gross margin of 86% reflected benefit from a one-time tariff refund providing about 100 basis points of boost, which is not expected to repeat.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Bullish Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +63%
above
Price vs 50-day avg +11%
above
RSI (14) 55
neutral
MACD trend Negative
52-week position 91%
near high
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +16%
trailing
6-month return +118%
trailing
YTD return +148%
this year
Relative strength +117%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $104 › 200d $71 — 50d above 200d
Institutional flow Accumulating
279 of 279 funds reported for Sep 30 · net +10.2M sh shares · +98 new
Insider flow Distributing
Net -$105.9K over 90 days · 100% sells
Short interest Falling
6.13% of shares out · ▼ -21.1% MoM · 2.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
279 holders — near 1-yr high, broad support
Squeeze score 60
elevated · 0–100
Fundamentals
Excellent
Revenue growth +51%
Y/Y
Gross margin 80%
expanding
EPS growth −783%
Y/Y
Free cash flow $170.7M
Valuation P/E 56.3
in line
Buyback $496.5M
remaining
Balance sheet $208.0M
net cash
Quant / Vol
risk profile
Very High
Volatility 51%
annualized · 1-yr
Max drawdown −38%
past year
ATR 4.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 6 of last 6
Latest guidance · from the 8-K filed Nov 2, 2026
Q4 2026
Revenue $249M – $251M
prior qtr $234.97M midpoint +6.4% QoQ
Non-GAAP income from operations Non-GAAP $81M – $83M
Non-GAAP operating margin Non-GAAP 33%
Full Year 2026
Revenue Raised $879M – $881M
Aug 4, 2026 $856M – $860M changed to Nov 2, 2026 $879M – $881M
prior FY $587.86M midpoint +49.7% Y/Y
Non-GAAP income from operations Non-GAAP Raised $266M – $268M
Aug 4, 2026 $236M – $244M changed to Nov 2, 2026 $266M – $268M
Non-GAAP operating margin Non-GAAP Raised 30%
Aug 4, 2026 28% changed to Nov 2, 2026 30%
Previous outlook earlier release · from the Earnings Call filed Aug 4, 2026

Still-open targets the latest release did not restate under the same label.

Share repurchase authorization · 2026 $300M
Prior guidance period ended · from the Earnings Call filed Aug 4, 2026
Revenue · Q3 2026 $223M – $225M
Income from operations · Q3 2026 $61M – $63M
Cylinder revenue contribution · remainder of 2025 $7M – $8M
Yield · this year 4.45%
Guided vs delivered · last 6 settled
Revenue Q3 2026
guided $223M – $225M
$234.97M Beat +4.9%
Revenue Q2 2026
guided $194M – $196M
$212.82M Beat +9.1%
Revenue Q1 2026
guided $171M – $173M
$182.31M Beat +6.0%
Revenue Q4 2025
guided $155M – $157M
$170.73M Beat +9.4%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
1 · 3 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+63% Bullish
Price vs 50-day avg
+11% Bullish
RSI (14)
55 Neutral
MACD trend
Negative Bearish
52-week position
91% Bullish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $104 › 200d $71 — 50d above 200d
Institutional flow Accumulating
279 of 279 funds reported for Sep 30 · net +10.2M sh shares · +98 new
Insider flow Distributing
Net -$105.9K over 90 days · 100% sells
Short interest Falling
6.13% of shares out · ▼ -21.1% MoM · 2.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
279 holders — near 1-yr high, broad support
Price context
position in its 52-week range
Range low $31 Now $115 · 91% Range high $123
vs 200-day avg +63% vs 50-day avg +11%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
LTM calculated billings 960.3M as of September 30, 2026 —
Number of clients 3,270 as of September 30, 2026 —
Non-GAAP diluted net income per share non-GAAP $0.59 Q2 2026 —
Non-GAAP net income attributable to common stockholders, diluted non-GAAP $49.15M Three Months Ended June 30, 2026 —
GAAP → non-GAAP reconciliation
GAAP GAAP net income (loss) attributable to common stockholders, diluted $43.13M
+$19.09M Stock-based compensation expense
+$1.32M Employer payroll tax expense related to stock-based compensation
+$224K Amortization of intangible assets
+$440K Acquisition-related expenses
-$14.98M Income tax effect of non-GAAP adjustments
-$78K Other dilutive
= Non-GAAP net income attributable to common stockholders, diluted $49.15M

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Health Information Services — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
HNGE
Hinge Health, Inc.
this stock
$9.38B +148.4% +50.6% 56.3 6.1%
VEEV
Veeva Systems Inc
$48.82B +35.1% +28.1% 49.4 2.4%
PMDIY
Pro Medicus Ltd.
$14.81B -14.6% — — 0.0%
BTSG
BrightSpring Health Services, Inc.
$14.17B +90.1% +28.2% 38.7 5.8%
TEM
Tempus AI, Inc.
$13.06B +21.3% +83.4% — 13.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
368
% held
83.4%
Reported
279 of 279
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
247
View
Short & Settlement
Short Interest Falling
Shares short
5.0M
Days to cover
2.4d
Change
-1.3M sh
View
Short Volume
Short vol %
32%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
312.7K
Value
$35.0M
As of
Oct 22, 2026
View
Off-Exchange
Off-exchange %
40.3%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$105.9K
Buyers / Sellers
0 / 2
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$587.9M
Net income (FY)
$-528.3M
EPS diluted
$-7.77
View
Buybacks
Authorized
$496.5M
Remaining
$496.5M
Spent Remaining
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 9, 2026
This year
17

Hinge Health reported nine-month revenue growth of 51%, primarily from existing clients, and net income of 136,217 (in thousands) versus a loss of 560,356 (in thousands).

View
Proposed Sales
Value
$24.6M
Shares
200.0K
Filed
Nov 12, 2026
View
Exempt Offerings
Offering
$400.0M
Filed
Dec 28, 2023
View
Earnings & Events
Webcasts
Last webcast
Nov 2, 2026
View
Investor Relations
Latest news
Hinge Health reports record third…
Published
Nov 2, 2026
View

Performance

5D 20D 120D MTD YTD
HNGE -0.3% +16.4% +117.8% +0.9% +148.4%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY -2.9% +17.5% +117.3% +1.1% +137.8%

Capital returns

Buyback program · as of Jul 29, 2026
Authorized
$496.50M
Spent (derived)
$0
Remaining
$496.50M
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1673743 CUSIP 433313103 13F (30d) 248 filings 245 filers Visit website Investor relations